168398-02-5

Basic information

• Product Name: GR 203040
• Synonyms: GR 203040;3-PiperidinaMine, N-[[2-Methoxy-5-(1H-tetrazol-1-yl)phenyl]Methyl]-2-phenyl-, (Hydrochloride) (1:2), (2S,3S)-;GR 203040(LS-113867);(2S,3S)-N-[[2-Methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl]-2-phenyl-3-piperidinamine hydrochloride (1:2)
• CAS NO: 168398-02-5
• Molecular Formula: C20H24 N6 O . 2 Cl H
• Molecular Weight: 437.366
• Mol File: 168398-02-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 560.4°Cat760mmHg
• Flash Point: 292.7°C
• Appearance: white to beige/
• Density: g/cm³
• Vapor Pressure: 1.37E-12mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: H2O: soluble10mg/mL, clear (warmed)
• CAS DataBase Reference: GR 203040(CAS DataBase Reference)
• NIST Chemistry Reference: GR 203040(168398-02-5)
• EPA Substance Registry System: GR 203040(168398-02-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 168398-02-5(Hazardous Substances Data)

Usage

General Description

GR 203040 is a chemical compound that belongs to a class of phosphodiesterase type 4 (PDE4) inhibitors. PDE4 is an enzyme that plays a role in the regulation of inflammation and immune responses in the body. By inhibiting the activity of PDE4, GR 203040 has the potential to reduce inflammation and provide therapeutic benefits in conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory diseases. Research studies have shown that GR 203040 exhibits anti-inflammatory and bronchodilator effects, making it a promising candidate for the development of new treatments for respiratory and inflammatory conditions. However, further research is needed to fully understand its potential benefits and potential side effects.

InChI:InChI=1/C20H24N6O.2ClH/c1-27-19-10-9-17(26-14-23-24-25-26)12-16(19)13-22-18-8-5-11-21-20(18)15-6-3-2-4-7-15;;/h2-4,6-7,9-10,12,14,18,20-22H,5,8,11,13H2,1H3;2*1H/t18-,20-;;/m0../s1

Relevant articles and documents

Piperidine derivatives

The present invention relates to piperidine derivatives of formula (I) STR1 wherein R 1 is a C 1-4 alkoxy group; R 2 is STR2 R 3 is a hydrogen or halogen atom; R 4 and R 5 may each independently represent a hydrogen or halogen atom, or aC 1-4 alkyl, C 1-4 alkoxy or trifluoromethyl group;R 6 is a hydrogen atom, a C 1-4 alkyl, (CH 2) m cyclopropyl, --S(O) n C 1-4 alkyl, phenyl,NR 7 R 8, CH 2 C(O)CF 3 or trifluoromethyl group;R 7 and R 8 may each independently represent a hydrogen atom, or a C 1-4 alkyl or acyl group;x represents zero or 1;n represents zero, 1 or 2;m represents zero or 1;and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation; and their use in the treatment of conditions mediated by tachykinins.